This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Randomized Controlled Trial  • Oncology  • Otolaryngology/ Head & Neck Surgery  • Neoplasms of Head & Neck  • Alert me on articles by topic

Drugs Target Liver, Gastric, Head and Neck Cancers

Tracy Hampton, PhD

JAMA. 2007;298:273-275.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Often with the odds stacked against them, most phase 3 trials for cancer treatment do not report long-lasting effects for patients. But some find that drugs can add months or years to the lives of study participants, who typically have late-stage disease and few, if any, other options.

Such was the case in several recently completed phase 3 trials, 1 testing sorafenib for the treatment of hepatocellular carcinoma (HCC), another evaluating cetuximab for head and neck cancer, and 2 assessing a drug called S-1 for combating gastric cancer. The trials' results were presented at the recent American Society of Clinical Oncology held here in June. Researchers and oncologists hope that the modest effects seen in these studies will be even greater if the drugs become available to patients with less advanced forms of cancer.

SORAFENIB TRIAL

In the multinational Sorafenib HCC Assessment Randomized Protocol (SHARP) trial of more . . . [Full Text of this Article]